Sign In
Buy AQST
$4.03
+0.100 (+2.54%)
At Close: Jun 03, 2026
Aquestive Therapeutics (AQST) Reports Q3 Loss, Lags Revenue Estimates
06:36pm, Wednesday, 05'th Nov 2025
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.
Aquestive Therapeutics (AQST) Projected to Post Quarterly Earnings on Wednesday
01:58am, Monday, 03'rd Nov 2025
Aquestive Therapeutics (NASDAQ: AQST - Get Free Report) is projected to announce its Q3 2025 results after the market closes on Wednesday, November 5th. Analysts expect the company to announce earning
WARREN, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful imp
Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?
10:41am, Wednesday, 15'th Oct 2025
Here is how Aquestive Therapeutics (AQST) and Arcturus Therapeutics (ARCT) have performed compared to their sector so far this year.
Aquestive Therapeutics: A Measured Bet
02:57am, Sunday, 12'th Oct 2025
Aquestive Therapeutics leverages its PharmFilm® platform to develop Anaphylm, a sublingual epinephrine film targeting a $1B+ U.S. market. AQST's management, including former EpiPen marketing leadersh
Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains?
10:01am, Friday, 10'th Oct 2025
Aquestive Therapeutics (AQST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri
Aquestive Therapeutics Broadens Patent Estate for Anaphylm™
07:00am, Wednesday, 08'th Oct 2025
WARREN, N.J., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful imp
Peanut allergy is a growing health concern, especially in children, with rising incidence and increased public awareness of its severity and risks. This
Aquestive Therapeutics (AQST) Soars 14.8%: Is Further Upside Left in the Stock?
05:41am, Monday, 22'nd Sep 2025
Aquestive Therapeutics (AQST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be m
Aquestive Therapeutics: No AdCom For Anaphylm Derisks January Approval Catalyst
12:40pm, Friday, 05'th Sep 2025
Aquestive Therapeutics's Anaphylm could be the first FDA-approved, non-invasive, orally delivered epinephrine for anaphylaxis, with a PDUFA date set for January 2026. FDA's decision not to convene an
AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA
12:06pm, Friday, 05'th Sep 2025
Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
10:41am, Thursday, 14'th Aug 2025
Here is how Aquestive Therapeutics (AQST) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock
06:28am, Thursday, 14'th Aug 2025
WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful imp
WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful imp
Aquestive Therapeutics, Inc. (AQST) Q2 2025 Earnings Call Transcript
10:19am, Tuesday, 12'th Aug 2025
Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q2 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants A. Ernest Toth - Chief Financial Officer Carl N.
